NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...
NEW YORK, March 1 (Reuters) - Amgen Inc. management moved on Thursday to reassure investors that the majority of use of its biggest product, the anemia drug Aranesp, will continue despite mounting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results